Welcome to our dedicated page for Avantor news (Ticker: AVTR), a resource for investors and traders seeking the latest updates and insights on Avantor stock.
Avantor, Inc. (NYSE: AVTR) is a life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. This news page aggregates company announcements, earnings updates and other disclosures so readers can follow how Avantor’s operations, portfolio and governance evolve over time.
Recent news releases describe Avantor’s participation in investor conferences, quarterly earnings reports, leadership and board appointments, and product and service developments. Examples include announcements about the timing of quarterly and full-year earnings releases and related conference calls, as well as participation in events such as the J.P. Morgan Healthcare Conference. These items provide context on how the company communicates with the investment community and presents its financial performance.
Product- and operations-focused news highlights areas such as bioprocessing, biomanufacturing and laboratory services. Avantor has reported the launch of a sterile sampling platform and PUPSIT assemblies for bioprocessing, the development of a biodegradable viral inactivation detergent recognized with an Edison Patent Award, and the expansion of its Centralized Service Center model with a facility serving the Greater Boston area. These updates illustrate how the company positions its tools and services within scientific and industrial workflows.
Corporate governance news includes the appointment of new directors and senior executives, such as additions to the Board of Directors and the creation of an Executive Vice President and Chief Operating Officer role. Together, these news items offer insight into Avantor’s strategic priorities, leadership changes and ongoing initiatives. Investors, analysts and industry participants can use this page to monitor company communications and official announcements over time.
Avantor, Inc. (NYSE: AVTR) announced that its CEO, Michael Stubblefield, will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference in New York on September 12, 2022, at 4:15 p.m. EDT. The session will be available via a live webcast on Avantor's investor website, with a replay accessible for 90 days post-event. Avantor is a global provider of critical products and services across various industries, serving over 225,000 customers globally.
Avantor reported second-quarter 2022 results with net sales of $1.91 billion, a 2.8% increase year-over-year. Core organic net sales grew 6.4%, primarily driven by a robust 20% growth in bioproduction. Net income rose to $187.4 million, and adjusted EBITDA increased 10.2% to $404.1 million. Diluted GAAP EPS stood at $0.28, while adjusted EPS was $0.37. Operating cash flow was $227.5 million, with free cash flow at $191.2 million. The company reduced adjusted net leverage to 3.9X, aligning with its long-term target range.
Avantor, Inc. (NYSE: AVTR) has appointed Kitty Sahin as EVP, Strategy and Corporate Development, effective immediately. With over 20 years of experience in corporate strategy and M&A, Sahin will lead Avantor’s strategic growth initiatives. CEO Michael Stubblefield emphasized the importance of her role in enhancing Avantor’s market position. Sahin previously held significant roles at companies like Novanta and Thermo Fisher. She expressed enthusiasm for contributing to Avantor's growth and success across business areas, benefiting all stakeholders.
Avantor, Inc. (NYSE: AVTR) will release its financial results for the second quarter of 2022 post-market on July 28, 2022. A conference call is scheduled for July 29, 2022, at 8:00 a.m. EDT for further discussions. The earnings press release and presentation will be available on Avantor's website. As a leading global provider in life sciences and advanced technologies, Avantor serves over 225,000 customer locations across more than 180 countries, highlighting its significant market presence. Investors are encouraged to tune in for insights into the company's performance.
Avantor (NYSE: AVTR) has announced a collaboration with GeminiBio to deliver custom hydrated solutions and cell culture media tailored for the biopharma industry. This partnership aims to enhance bioproduction workflows, particularly for emerging modalities like gene therapy, enabling faster product development from research through to commercialization. Avantor's strategic investments and acquisitions complement this initiative, demonstrating its commitment to optimizing customer processes and improving efficiency in biomanufacturing.
Avantor (NYSE: AVTR), a global leader in mission-critical products and services, announced that its President and CEO, Michael Stubblefield, will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on June 14, 2022, at 11:00 a.m. EDT. The event will take place in Rancho Palos Verde, California. Interested parties can access a live webcast on the company's investor section of their website, with a replay available for 90 days. Avantor serves over 225,000 customers across various industries, emphasizing innovation in life sciences and advanced technologies.
Summary not available.
Avantor, Inc. (NYSE: AVTR) announced the automatic conversion of its 6.250% Series A Mandatory Convertible Preferred Stock into common stock on May 16, 2022. Each share of Preferred Stock will convert into 3.0395 shares of common stock, with cash paid for any fractional shares. Holders of record as of May 1, 2022 will also receive a final quarterly cash dividend of $0.78 per share payable on the conversion date.
Avantor, Inc. (NYSE: AVTR) has elected Jonathan Peacock, 64, as the new chairman of its board of directors, effective after the annual stockholder meeting today. Peacock succeeds Raj Gupta, who is retiring. Peacock, a board member since 2017, highlighted the company's potential for growth and scientific breakthroughs. He has extensive experience, having held leadership roles at Amgen and Novartis. Avantor is a global provider of mission-critical products and services for life sciences and advanced technologies, serving over 225,000 customers in more than 180 countries.
Avantor (NYSE: AVTR) has partnered with Cytovance Biologics to enhance plasmid DNA development for biopharma clients. This collaboration will leverage Cytovance's cGMP manufacturing capabilities, significantly boosting Avantor's offerings in the rapidly growing gene therapy sector. As demand for therapeutic biologics rises, this partnership is positioned to support increased manufacturing capacity and meet the needs of emerging mRNA and viral vector therapies. Both companies aim to expand their global reach and provide critical materials for research and commercialization.